Douglas E. Brenneman

Douglas E. Brenneman

Company: Neuropathix, Inc.

Job title: Director of Pharmacology


GPR55, A Sentinel for Inflammation in Chemotherapy-Induced Peripheral Neuropathy 2:30 pm

Paclitaxel increases acute GPR55 expression in the cell bodies of DRG neurons KLS-13019, a novel cannabinoid, can act as a GPR55 antagonist to lysophosphatidylinosital-mediated increases in b-arrestin of DiscoverX cells KLS-13019 can reverse paclitaxel-induced increases in multiple cytokines, NLRP3 and GPR55 expression in high content assays of DRG neuronsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.